MATERIALS LICENSE
SUPPLEMENTARY SHEET

CORRECTED COPY

License number
35-19898-01
Docket or Reference number

Amendment No. 03

City of Faith Medical and Research
Center
8181 S. Lewis
P.O. Box 36000
Tulsa, Oklahoma 74136

G 3

In accordance with letter dated July 28, 1982, License Number 35-19898-01 is amended as follows:

TO ADD:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
H. Iodine 131	H. Iodide	H. 500 millicuries
I. Phosphorus 32	I. Colloidal	I. 500 millicuries

9. Authorized use

H. For treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.
I. For intracavitary treatment of malignant effusions.

Conditions 12. and 17. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Gilbert Maulsby, M.D.	Groups I, II, III, and VI Americium 241 Anatomical Marker Xenon 133 Depleted uranium for shielding
Patrick D. Lester, M.D.	Groups I, II and III Xenon 133

5

2

MATERIALS LICENSE
SUPPLEMENTARY SHEET

CORRECTED COPY

License number
35-19898-01
Docket or Reference number

Amendment No. 03

12. continued

Kenneth K. Wheatley, Jr., M.D.	Groups I, II, and III Xenon 133
Charles R. Gosnell, M.D.	Groups I, II and III Xenon 133 Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma Phosphorus 32 as colloidal chromic phosphate for intracavitary treatment of malignant effusions
Phillip W. Jones, M.D.	Group VI

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated November 3, 1981, with Model ALARA Program; and letters dated January 11, 1982, May 21, 1982, and July 28, 1982. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

Conditions 19. and 20. are added:

19. Patients containing Cobalt 60, Cesium 137 or Iridium 192 implants shall remain hospitalized until a source count and surveys made with an appropriate radiation detection instrument indicate that all implants have been removed. The results of these surveys shall be recorded and maintained for inspection by the Commission for five (5) years from the time the implants are removed.

20. Patients containing Iodine 131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold 198 shall remain hospitalized until the residual activity is 30 millicuries or less.

OCT 28 1982

Date

FOR THE U.S. NUCLEAR REGULATORY COMMISSION
Original signed by
P. A. Siemon

By Material Licensing Branch
Division of Fuel Cycle and
Material Safety
Washington, D. C. 20555

10/27/82